Target Name: ZNF558
NCBI ID: G148156
Review Report on ZNF558 Target / Biomarker Content of Review Report on ZNF558 Target / Biomarker
ZNF558
Other Name(s): ZN558_HUMAN | ZNF558 variant 1 | Zinc finger protein 558 (isoform 1) | Zinc finger protein 558 | zinc finger protein 558 | Zinc finger protein 558, transcript variant 1

ZNF558: A Potential Drug Target and Biomarker for Neurological Disorders

ZNF558 (ZN558_HUMAN), a protein encoded by the ZNF5 gene, is a key regulator of neural development, cell survival, and growth. The ZNF5 gene is located on chromosome 6 (6p) and has been implicated in various neurological and psychiatric disorders, including autism, schizophrenia, and cancer. ZNF558 has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The ZNF5 gene is a member of the TGF-β signaling pathway, which is a well-established regulator of cellular growth, differentiation, and survival. The TGF-β pathway is activated in response to various signaling cues, including growth factors, physical stress , and cellular stress. The ZNF5 gene is critical for the formation of the TGF-β signaling pathway, as it encodes a protein that can inhibit the negative effects of TGF-β signaling on cellular growth and survival.

ZNF558 is a 21-kDa protein that is expressed in various tissues and cells, including neurons, astrocytes, and microglia. It is involved in the regulation of cellular processes such as cell growth, apoptosis, and survival. ZNF558 has been shown to play a role in the development and progression of various neurological and psychiatric disorders, including autism, schizophrenia, and cancer.

In cancer, ZNF558 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. It has been shown to promote the growth and survival of cancer cells, and to inhibit the progression and apoptosis of cancer cells. ZNF558 has also been shown to play a role in the regulation of the immune response, and has been implicated in the development of autoimmune disorders.

As a potential drug target, ZNF558 has been shown to be a good candidate for the treatment of various neurological and psychiatric disorders, including cancer, neurodegenerative diseases, and autoimmune disorders. ZNF558 has been shown to interact with several drug targets, including TGF-β , NF-kappa-B, and PDGF. It has also been shown to modulate the activity of several proteins, including cyclin D1, p21, and p53.

In addition to its potential therapeutic applications, ZNF558 also has significant implications for the study of neurodegenerative diseases. The ZNF5 gene has been implicated in the development and progression of several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The ZNF558 protein has been shown to be involved in the regulation of neurodegenerative disease, and may be a useful biomarker for the diagnosis and treatment of these disorders.

In conclusion, ZNF558 is a protein that has significant implications for our understanding of the regulation of neural development, cell survival, and growth. Its potential as a drug target and biomarker make it an attractive target for the development of new treatments for a variety of neurological and psychiatric disorders, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of ZNF558 in these processes, and to develop effective treatments based on its properties.

Protein Name: Zinc Finger Protein 558

Functions: May be involved in transcriptional regulation

The "ZNF558 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF558 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF559 | ZNF559-ZNF177 | ZNF560 | ZNF561 | ZNF561-AS1 | ZNF562 | ZNF563 | ZNF564 | ZNF565 | ZNF566 | ZNF566-AS1 | ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579 | ZNF580 | ZNF582 | ZNF582-DT | ZNF583 | ZNF584 | ZNF585A | ZNF585B | ZNF586 | ZNF587 | ZNF587B | ZNF589 | ZNF592 | ZNF593 | ZNF594 | ZNF594-DT | ZNF595 | ZNF596 | ZNF597 | ZNF598 | ZNF599 | ZNF600 | ZNF603P | ZNF605 | ZNF606 | ZNF607 | ZNF608 | ZNF609 | ZNF610 | ZNF611 | ZNF613 | ZNF614 | ZNF615 | ZNF616 | ZNF618 | ZNF619 | ZNF620 | ZNF621 | ZNF622 | ZNF623 | ZNF624 | ZNF625 | ZNF625-ZNF20 | ZNF626 | ZNF627 | ZNF628 | ZNF629 | ZNF630 | ZNF638 | ZNF639 | ZNF641 | ZNF644 | ZNF646 | ZNF648 | ZNF649 | ZNF652 | ZNF652-AS1 | ZNF653 | ZNF654 | ZNF655 | ZNF658 | ZNF658B | ZNF66 | ZNF660 | ZNF662 | ZNF663P | ZNF664 | ZNF664-RFLNA | ZNF665 | ZNF667 | ZNF667-AS1 | ZNF668 | ZNF669 | ZNF670